FDA Approves Tildrakizumab for Active Psoriatic Arthritis

The US Food and Drug Administration has approved tildrakizumab-asmn, marketed as Ilumya by Sun Pharma, for the treatment of adults with active psoriatic arthritis, according to Thedermdigest.

The reported decision adds an active psoriatic arthritis indication for tildrakizumab-asmn. Thedermdigest identifies tildrakizumab as an interleukin-23 blocker and describes psoriatic arthritis as a complex and chronic disease.

FDA approval for active psoriatic arthritis

The FDA approval applies to adults with active psoriatic arthritis. Thedermdigest reported the regulatory action involving tildrakizumab-asmn and identified Ilumya as the Sun Pharma product name.

For medical sales professionals following dermatology and rheumatology developments, the event is the FDA-approved use of tildrakizumab-asmn in the adult active psoriatic arthritis population. Communications about the decision can center on the indication reported by Thedermdigest: treatment of adults with active psoriatic arthritis.

The source also characterizes the medicine by its mechanism class, calling tildrakizumab an interleukin-23 blocker. The FDA action concerns the product’s use in active psoriatic arthritis, rather than changing the disease description provided by the publisher.

Previously reported plaque psoriasis use

According to Thedermdigest, tildrakizumab is also approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

That plaque psoriasis use and the newly reported active psoriatic arthritis use involve distinct patient descriptions. The plaque psoriasis approval cited by Thedermdigest is for adults with moderate-to-severe disease who are candidates for systemic therapy or phototherapy. The active psoriatic arthritis approval is for adults with active disease.

Key points from the report

• The FDA approved tildrakizumab-asmn for adults with active psoriatic arthritis.
• The product is marketed as Ilumya by Sun Pharma.
• Thedermdigest describes tildrakizumab as an interleukin-23 blocker.
• The therapy is also approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The FDA decision, as reported by Thedermdigest, establishes an approved active psoriatic arthritis indication for tildrakizumab-asmn while the publisher also notes its approval in the specified plaque psoriasis population.